

CRITICAL OUTCOME ANNOUNCES NO MATERIAL CHANGE

London, Ontario (June 8, 2016): Critical Outcome Technologies Inc. (TSX Venture: COT; OTCQB: COTQF) (“COTI” or the “Company”) is issuing this press release in response to a request by the Investment Industry Regulatory Organization of Canada (“IIROC”) to comment on recent trading activity in our stock.

The Company announces that it is not aware of any material, undisclosed corporate developments and has no material change to report at this time. The Company will keep the market informed as required.

The Company has become aware that there are certain articles published by Marketbeat.com, American Banking and Market News, and associated financial news websites that inaccurately identify Critical Outcome Technologies Inc. as the subject of several news reports that relate to a different company. Both companies use the same stock symbol “COT” with COTI being listed on the TSXV and the other company listed on the NYSE. The Company asserts that the articles published by these sources and the information contained therein are not in any way related to the Company.

Investors are encouraged to consult with the Company’s Investor Relations directly for information regarding its operations and developments at ppapi@criticaloutcome.com or (508) 444-6790.

About Critical Outcome Technologies Inc.

COTI is a clinical stage biopharmaceutical company advancing the treatment of cancer through targeted therapeutics. The Company’s lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial therapeutic indication is in gynecologic cancers, which includes ovarian, cervical, and endometrial cancers; treatment of patients in a Phase 1 clinical trial began at MD Anderson Cancer Center in February 2016. The Company has secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other cancer indications such as head and neck, Li-Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI-2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter or visit our award winning website: www.criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information contact:

Dr. Wayne Danter
President & CEO
Tel: 519-858-5157
Email: wdanter@criticaloutcome.com

Paul Papi
Vice President Investor Relations
Tel: 508-444-6790 / 519-858-5157
Email: ppapi@criticaloutcome.com